C A Uyl-de Groot - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

C A Uyl-de Groot

Showing results (21-30 of 67) with videos related to

Pageof 7

Sort By:

European Journal of Haematology|February 8, 2005

Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The NetherlandsM T Groot, P J Lugtenburg, J Hornberger, et al.

Nederlands Tijdschrift Voor Geneeskunde|July 18, 2000

[Diagnosis and treatment of non-Hodgkin lymphoma in Netherlands: variation in guidelines and in practice]L M Faber, M van Agthoven, C A Uyl-de Groot, et al.

British Journal of Haematology|April 8, 1998

Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemiaC A Uyl-de Groot, B Löwenberg, E Vellenga, et al.

European Urology|February 26, 2003

Costs of prostate cancer, metastatic to the bone, in the NetherlandsM T Groot, C G G Boeken Kruger, R C M Pelger, et al.

Journal of Hematotherapy & Stem Cell Research|March 29, 2001

Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the netherlandsC A Uyl-de Groot, J Gelderblom-den Hartog, P C Huijgens, et al.

Pharmacoeconomics|August 5, 1997

Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomised placebo-controlled trialC A Uyl-de Groot, E Vellenga, E G de Vries, et al.

European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|August 3, 2013

Cetuximab in locally advanced squamous cell carcinoma of the head and neck: generalizability of EMR 062202-006 trial resultsNaomi van der Linden, C W M van Gils, C P Pescott, et al.

Clinical Otolaryngology : Official Journal of ENT-UK ; Official Journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery|July 27, 2007

Free radial forearm flap versus pectoralis major myocutaneous flap reconstruction of oral and oropharyngeal defects: a cost analysisR de Bree, R Reith, J J Quak, et al.

Journal of the Neurological Sciences|August 7, 2021

An implantable device to treat multiple sclerosis: A discrete choice experiment on patient preferences in three European countriesL A Visser, S P I Huls, C A Uyl-de Groot, et al.

Rhinology|July 3, 2002

Cost analysis of regular and filgrastim treatment in patients with refractory chronic rhinosinusitisM van Agthoven, C A Uyl-de Groot, W J Fokkens, et al.

Pageof 7

Search research articles

Showing results (21-30 of 67) with videos related to

Sort By:

Pageof 7

European Journal of Haematology|February 8, 2005

Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The NetherlandsM T Groot, P J Lugtenburg, J Hornberger, et al.

Nederlands Tijdschrift Voor Geneeskunde|July 18, 2000

[Diagnosis and treatment of non-Hodgkin lymphoma in Netherlands: variation in guidelines and in practice]L M Faber, M van Agthoven, C A Uyl-de Groot, et al.

British Journal of Haematology|April 8, 1998

European Urology|February 26, 2003

Costs of prostate cancer, metastatic to the bone, in the NetherlandsM T Groot, C G G Boeken Kruger, R C M Pelger, et al.

Journal of Hematotherapy & Stem Cell Research|March 29, 2001

Costs of diagnosis, treatment, and follow up of patients with acute myeloid leukemia in the netherlandsC A Uyl-de Groot, J Gelderblom-den Hartog, P C Huijgens, et al.

Pharmacoeconomics|August 5, 1997

Cetuximab in locally advanced squamous cell carcinoma of the head and neck: generalizability of EMR 062202-006 trial resultsNaomi van der Linden, C W M van Gils, C P Pescott, et al.

Clinical Otolaryngology : Official Journal of ENT-UK ; Official Journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery|July 27, 2007

Free radial forearm flap versus pectoralis major myocutaneous flap reconstruction of oral and oropharyngeal defects: a cost analysisR de Bree, R Reith, J J Quak, et al.

Journal of the Neurological Sciences|August 7, 2021

An implantable device to treat multiple sclerosis: A discrete choice experiment on patient preferences in three European countriesL A Visser, S P I Huls, C A Uyl-de Groot, et al.

Rhinology|July 3, 2002

Cost analysis of regular and filgrastim treatment in patients with refractory chronic rhinosinusitisM van Agthoven, C A Uyl-de Groot, W J Fokkens, et al.

Pageof 7